Edition:
United Kingdom

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

88.25EUR
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
€88.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
143,047
52-wk High
€124.90
52-wk Low
€76.45

Latest Key Developments (Source: Significant Developments)

Morphosys And I-Mab Biopharma Announce First Patient Dosed In Phase 3 Clinical Study Of Mor202/Tj202 In Multiple Myeloma
Monday, 29 Apr 2019 

April 29 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS AND I-MAB BIOPHARMA ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 CLINICAL STUDY OF MOR202/TJ202 IN MULTIPLE MYELOMA.  Full Article

Morphosys Announces That Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Familial Adenomatous Polyposis
Monday, 15 Apr 2019 

April 15 (Reuters) - MorphoSys AG ::IN CONNECTION WITH START OF CLINICIAL DEVELOPMENT IN FAP, MORPHOSYS RECEIVED A MILESTONE PAYMENT FROM JANSSEN.ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO FAMILIAL ADENOMATOUS POLYPOSIS.MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB INTO FAMILIAL ADENOMATOUS POLYPOSIS.MILESTONE PAYMENT FINANCIAL DETAILS WERE NOT DISCLOSED..  Full Article

Morphosys Says Nominates New Candidate For Supervisory Board
Wednesday, 10 Apr 2019 

April 10 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS NOMINATES NEW CANDIDATE FOR SUPERVISORY BOARD.SUPERVISORY BOARD HAS NOMINATED SHARON CURRAN AS CANDIDATE TO BE ELECTED AS NEW ADDITIONAL SUPERVISORY BOARD MEMBER AT COMPANY'S AGM.SUPERVISORY BOARD WILL PROPOSE RE-ELECTION OF KRISJA VERMEYLEN, WHOSE TERM OF OFFICE WOULD EXPIRE WITH CONCLUSION OF AGM 2019.  Full Article

MorphoSys AG FY Revenue Rose 14 Percent To 76.4 Million EUR
Wednesday, 13 Mar 2019 

March 13 (Reuters) - MorphoSys AG ::FY NET LOSS -56.2 MILLION EUR VERSUS -69.8 MILLION EUR LOSS YEAR AGO.FY REVENUE ROSE 14 PERCENT TO 76.4 MILLION EUR.FY EBIT LOSS EUR 59.1 MILLION VERSUS LOSS OF EUR 67.6 MILLION IN 2017.REVENUES IN 2019 FINANCIAL YEAR ARE EXPECTED TO BE BELOW THOSE ACHIEVED IN 2018.FOR FY 2019, MORPHOSYS EXPECTS TO GENERATE GROUP REVENUES IN RANGE OF EUR 43 MILLION TO EUR 50 MILLION.EXPECTS 2019 EBIT LOSS OF EUR 127 MILLION TO EUR 137 MILLION.  Full Article

Morphosys: Licensee Janssen Receives U.S. FDA Approval For Tremfya(R) One-Press Patient-Controlled Injector For Adults With Moderate-To-Severe Plaque Psoriasis
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - MORPHOSYS AG ::ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED U.S. FDA APPROVAL FOR TREMFYA(R) ONE-PRESS PATIENT-CONTROLLED INJECTOR FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.  Full Article

Morphosys Announces Settlement In Patent Lawsuit With Janssen And Genmab
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - MorphoSys AG ::ANNOUNCES SETTLEMENT IN PATENT LAWSUIT WITH JANSSEN AND GENMAB.PARTIES TO DISPUTE HAVE AGREED TO DROP MUTUAL CLAIMS RELATED TO THIS LITIGATION.  Full Article

Morphosys Says Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Ulcerative Colitis
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO ULCERATIVE COLITIS.MORPHOSYS AG- JANSSEN HAS INITIATED A PROOF-OF-CONCEPT PHASE 2A CLINICAL TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS .MORPHOSYS IS ELIGIBLE TO CERTAIN MILESTONE PAYMENTS AND RECEIVES ROYALTIES ON NET SALES OF TREMFYA (R).  Full Article

Morphosys Licensee Janssen Announces Psoriasis Data
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - MorphoSys AG ::MORPHOSYS'S LICENSEE JANSSEN ANNOUNCES DATA FROM PHASE 3 HEAD-TO-HEAD STUDY ECLIPSE DEMONSTRATING SUPERIORITY OF TREMFYA(R) VERSUS. COSENTYX(R) AS MEASURED BY PASI 90 AT WEEK 48 IN TREATMENT OF PLAQUE PSORIASIS.LICENSEE JANSSEN HAS ANNOUNCED THAT RESULTS FROM ECLIPSE STUDY DEMONSTRATED THAT TREMFYA^(R) (GUSELKUMAB) WAS SUPERIOR TO COSENTYX^(R) (SECUKINUMAB) IN TREATING ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS FOR PRIMARY ENDPOINT OF A PASI 90 RESPONSE AT WEEK 48.  Full Article

Morphosys - Guselkumab Shows Superior Responses To Secukinumab In The Treatment Of Psoriasis
Friday, 7 Dec 2018 

Dec 7 (Reuters) - MorphoSys AG ::DGAP-ADHOC: AD HOC: MORPHOSYS ANNOUNCES THAT ACCORDING TO A PRESENTATION TITLE AT AN UPCOMING CONFERENCE, GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES TO SECUKINUMAB AT WEEK 48 IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS.MORPHOSYS EXPECTS THAT THIS ANNOUNCEMENT RELATES TO AN UPCOMING PRESENTATION OF CLINICAL DATA FROM SO CALLED "ECLIPSE" CLINICAL STUDY.ECLIPSE TRIAL HAS BEEN CONDUCTED BY MORPHOSYS' LICENSEE JANSSEN, COMPARING EFFICACY OF GUSELKUMAB TREMFYA^(R) TO SECUKINUMAB COSENTYX^(R), FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS, AT WEEK 48.TREMFYA^(R) IS A HUMAN ANTI-IL-23 MONOCLONAL ANTIBODY DEVELOPED BY JANSSEN THAT WAS GENERATED UTILIZING MORPHOSYS' PROPRIETARY HUCAL ANTIBODY TECHNOLOGY.  Full Article

I-Mab Biopharma, Morphosys Announce China IND Submission Of TJ202/MOR202
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - MorphoSys AG ::I-MAB BIOPHARMA AND MORPHOSYS ANNOUNCE CHINA IND SUBMISSION OF TJ202/MOR202.MORPHOSYS AG- I-MAB HAS SUBMITTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO CHINA NATIONAL DRUG ADMINISTRATION (CNDA) FOR TJ202/MOR202.  Full Article

German stocks - Factors to watch on May 22

BERLIN/FRANKFURT, May 22 The following are some of the factors that may move German stocks on Wednesday: